


OSTEOPOROSIS HIGH COST DRUG TREATMENT PATHWAY (POST-MENOPAUSAL ADULTS ONLY)

Approved by NHS Surrey Heartlands ICS Area Prescribing Committee - **March 2025**



‡ Patients stopping denosumab, teriparatide, romosozumab and abaloparatide require sequential therapy strategy typically involving an antiresorptive drug

Abbreviations: IV, intravenous; TA, technology appraisal

Pathway adapted from NICE TA991 committee evidence papers, and adopted by APC as a temporary measure in November 2024